The Role of Gratitude in Spiritual Well-Being in Asymptomatic Heart Failure Patients

Paul J. Mills, Laura Redwine, Kathleen Wilson, Meredith A. Pung, Kelly Chinh, Barry H. Greenberg, Ottar Lunde, Alan Maisel, and Ajit Raisinghani University of California, San Diego

Alex Wood University of Stirling

Deepak Chopra University of California, San Diego, and Chopra Center for Wellbeing, Carlsbad, California

Spirituality and gratitude are associated with well-being. Few if any studies have examined the role of gratitude in heart failure (HF) patients or whether it is a mechanism through which spirituality may exert its beneficial effects on physical and mental health in this clinical population. This study examined associations between gratitude, spiritual well-being, sleep, mood, fatigue, cardiac-specific selfefficacy, and inflammation in 186 men and women with Stage B asymptomatic HF (age 66.5 years \pm 10). In correlational analysis, gratitude was associated with better sleep (r = -.25, p < .01), less depressed mood (r = -.41, p < .01), less fatigue (r = -.46, p < .01), and better self-efficacy to maintain cardiac function (r = .42, p < .01)p < .01). Patients expressing more gratitude also had lower levels of inflammatory biomarkers (r = -.17, p < .05). We further explored relationships among these variables by examining a putative pathway to determine whether spirituality exerts its beneficial effects through gratitude. We found that gratitude fully mediated the relationship between spiritual well-being and sleep quality (z = -2.35, SE = .03, p = .02) and also the relationship between spiritual well-being and depressed mood (z = -4.00, SE = .075, p < .001). Gratitude also partially mediated the relationships between spiritual well-being and fatigue (z = -3.85, SE = .18, p < .001) and between spiritual well-being and self-efficacy (z = 2.91, SE = .04, p = .003). In sum, we report that gratitude and spiritual well-being are related to better mood and sleep, less fatigue, and more self-efficacy, and that gratitude fully or partially mediates the beneficial effects of spiritual well-being on these endpoints. Efforts to increase gratitude may be a treatment for improving well-being in HF patients' lives and be of potential clinical value.

Keywords: heart failure, gratitude, spiritual well-being, inflammation

Paul J. Mills, Department of Family Medicine and Public Health, Department of Psychiatry, and UC San Diego Center of Excellence for Research and Training in Global Integrative Health, University of California, San Diego, and Chopra Center for Wellbeing, Carlsbad, California; Laura Redwine, Department of Psychiatry and UC San Diego Center of Excellence for Research and Training in Global Integrative Health, University of California, San Diego; Kathleen Wilson and Meredith A. Pung, Department of Family Medicine and Public Health, University of California, San Diego; Kelly Chinh, Department of Psychiatry, University of California, San Diego; Barry H. Greenberg, Ottar Lunde, Alan

Maisel, and Ajit Raisinghani, Department of Medicine, University of California, San Diego; Alex Wood, Department of Behavioral Science, University of Stirling; Deepak Chopra, Department of Family Medicine and Public Health, University of California, San Diego, and Chopra Center for Wellbeing.

This work was supported by Grants HL-073355, HL-096784, and 1UL1RR031980-01 from the National Institutes of Health and a grant from the Greater Good Science Center, Berkeley, CA.

Correspondence concerning this article should be addressed to Paul J. Mills, UCSD, 9500 Gilman Drive #0725, La Jolla, CA 92093-0725. E-mail: pmills@ucsd.edu

Gratitude unlocks the fullness of life. . . . It turns denial into acceptance, chaos into order, confusion into clarity. . . . It turns problems into gifts, failures into success, and mistakes into important events. Gratitude makes sense of our past, brings peace for today, and creates a vision for tomorrow.

-Melodie Beattie

Heart failure (HF) is a major public health concern, affecting over 6 million Americans, with rates expected to nearly triple over the next few decades as the population ages (Krum & Stewart, 2006). It is the end stage of most cardiac anomalies, with the annual number of hospitalizations exceeding 1 million, and direct costs in the United States exceeding \$40 billion/year (Desai & Stevenson, 2012; Wang, Zhang, Ayala, Wall, & Fang, 2010).

In the field of behavioral cardiology (Rozanski, 2014), there is increasing interest in examining associations between positive psychological attributes such as spirituality and gratitude, potential mechanisms of their action, and importantly, associations with clinical outcomes (Dubois et al., 2012; Huffman et al., 2011; Sacco, Park, Suresh, & Bliss, 2014). In many populations, spirituality or religious wellness are associated with better mental and physical health. In a recent meta-analytic review, for example, Bonelli and Koenig (2013) reported that religious-spiritual involvement is correlated with better mental health, including less depression (Bonelli & Koenig, 2013), although such associations are not always observed (Morgenstern et al., 2011). In patients with symptomatic HF, there is a positive correlation between spiritual well-being and better mental health (Whelan-Gales, Quinn Griffin, Maloni, & Fitzpatrick, 2009). In addition, symptomatic HF patients with higher measures of spiritual well-being have better HF-related health status (Bekelman et al., 2009).

Therapeutically, there is increasing recognition of the value of embracing multidisciplinary therapeutic approaches in HF that include spirituality as part of more routine psychosocial support (Naghi, Philip, Phan, Cleenewerck, & Schwarz, 2012). Spirituality-based interventions for improving mood and well-being in cardiovascular disease populations have shown promising outcomes and demonstrated good adherence in several pilot studies. For example, Delaney, Barrere, and Helming (2011) reported reduced depression scores among community-dwelling patients with

cardiovascular disease following an individualized 1-month spirituality-based intervention on health-related outcomes. Warber et al. (2011) examined the effects of a nondenominational spiritual retreat on depression and other measures of well-being in postacute coronary syndrome patients. A 4-day spiritual retreat intervention included guided imagery, meditation, drumming, journal writing, and nature-based activities. A control intervention included nutrition education, exercise, and stress management. Both retreat groups received follow-up phone coaching biweekly for up to 3 months. Compared with the control group, patients assigned to the spiritual retreat group had significantly lower depression scores postintervention, which were maintained 3 months later.

Gratitude is considered a positive psychological factor that has also been associated with well-being in some populations. According to Büssing et al. (2014), in clinical populations feelings of gratitude and awe facilitate perceptions and cognitions that go beyond the focus of the illness and include positive aspects of one's personal and interpersonal reality, even in the face of disease. According to Wood, Froh, and Geraghty (2010), gratitude is part of a wider life orientation toward noticing and appreciating the positive aspects of life. Gratitude can be attributed to an external source such as an animal, person, or nonhuman (e.g., God, the cosmos), and may be part of a vaster perspective of noticing and appreciating the positive in the world (Wood et al., 2010). There are individual differences in dispositional gratitude, which entails how frequently and intensely people experience the emotion of gratitude, the range of events which elicit the emotion, and in the interpretation of social situations (McCullough, Emmons, & Tsang, 2002; Wood, Maltby, Stewart, Linley, & Joseph, 2008). Longitudinal studies suggest that higher levels of gratitude are directly linked to improvements in perceived social support as well as reduced stress and depression, and that these direct effects are not explained by personality factors (Wood et al., 2008).

Gratitude has theological origins and the importance of its development and practice is emphasized in the majority of world religions. Prayer frequency has been found to increase gratitude (Lambert, Graham, & Fincham, 2009), and in this way gratitude may serve as a

pathway through which spirituality exerts its known positive effects on physical and mental health.

The American College of Cardiology/ American Heart Association (ACC/AHA) HF staging system denotes Stage B patients as asymptomatic but at high risk for developing symptomatic (Stage C) HF (Hunt et al., 2005a). Stage B consists of patients who have developed structural heart disease (e.g., previous myocardial infarction, asymptomatic valvular disease) with specific left ventricular (LV) dysfunction that is associated with inflammation and the development of HF but who have never shown signs or symptoms of HF. Stage C HF further includes both structural or functional abnormality, increased inflammation, and exercise limitation from dyspnea or fatigue, whereas Stage D includes severe "end-stage" HF (Eisen, Benderly, Behar, Goldbourt, & Haim, 2014; Viganego & Le Jemtel, 2007). The ACC/AHA HF staging system emphasizes both the evolution and the progression of chronic HF and seeks to identify and implement early therapeutic interventions to ultimately reduce morbidity and mortality (Hunt et al., 2005b). The Stage B level of disease presents an important therapeutic window into potentially halting disease progression and improving quality of life. Progression from Stage B HF to symptomatic HF is associated with a fivefold increase in mortality risk (Ammar et al., 2007).

Within the growing field of studying relationships between gratitude and well-being, few studies have examined HF populations, and this is despite recent studies describing the importance of psychosocial resources such as gratitude in alleviating the struggles associated with living with symptomatic HF (Sacco et al., 2014). The purpose of this study therefore was to examine associations between spiritual wellbeing, gratitude, and physical and mental health in Stage B HF patients and to examine a potential pathway (i.e., gratitude) through which spiritual well-being may promote physical and mental health benefits.

Method

Participants

The sample consisted of 186 men and women with AHA/ACC classification Stage B HF with

a diagnosis for at least 3 months. Patients were recruited from the cardiology clinics at the University of California San Diego Medical Centers and the Veterans Affairs San Diego Health care System (VASDHS). Presence of Stage B HF was defined as structural heart disease based on recommendations and cut-points from the American Society of Echocardiography guidelines (Lang et al., 2005), including LV hypertrophy (defined as mean LV wall thickness of septum and posterior wall ≥12 mm), LV enlargement (at least moderate in severity, defined as LV end diastolic diameter \geq 64 mm in men or \geq 58 mm in women, or LV mass index ≥ 132 in men or ≥ 109 in women), LV systolic dysfunction (defined as LV ejection fraction <55% or wall motion abnormality), LV diastolic dysfunction, asymptomatic valvular heart disease of at least moderate severity, or previous myocardial infarction, but without signs or symptoms of HF. Left ventricular ejection fraction (%LVEF) was assessed by echocardiography as part of the patient's routine medical evaluation.

Protocol

The protocol was approved by the UCSD and VASDHS Institutional Review Boards and participants gave written informed consent. The study was carried out in accordance with the Declaration of Helsinki principles. On presentation to the laboratory, a blood draw was obtained using a 21- or 23-gauge butterfly needle and participants completed a packet of psychosocial questionnaires.

Measures

Gratitude. Gratitude was assessed with the GQ-6 (Froh et al., 2011; McCullough et al., 2002). The GQ-6 is a psychometrically sound self-administered 6-item scale designed to measure trait gratitude. Internal consistency of the GQ-6 in this cardiac population was high, with a Cronbach's alpha of 0.92.

Spiritual well-being. The Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT–SP12) was used to assess spiritual well-being (Peterman, Fitchett, Brady, Hernandez, & Cella, 2002). The FACIT–SP12 is a 12-item scale designed to measure the extent to which patients experienced spiritual

well-being over the previous week. Internal consistency reliability coefficients have ranged from .81 to .88, and convergent validity estimates show moderate to strong correlations with other measures of spirituality and religiousness (Peterman et al., 2002). In this cohort, Cronbach's alpha for the FACIT–SP12 was 0.85.

Depressive symptom severity. Symptoms of depression were assessed with the 21-item Beck Depression Inventory (BDI–IA), where scores ≥10 indicate possible clinical depression (Beck, 1978). The BDI–IA assesses symptoms related to sadness, feelings of guilt, suicidal ideation, and changes in appetite and body weight, among other characteristics. The BDI–IA shows high reliability and structural validity and capacity to discriminate between depressed and nondepressed participants with broad applicability for research and clinical practice worldwide (Wang & Gorenstein, 2013). The BDI–IA Cronbach's alpha for this sample was 0.85.

Sleep quality. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality (Smyth, 2000). The PSQI is widely used in sleep research and measures sleep disturbance and usual sleep habits and has high internal reliability and construct validity (Carpenter & Andrykowski, 1998). In addition to component scores in domains of subjective sleep quality, latency and duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction, the PSQI also yields a global score (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). Cronbach's alpha for the PSQI global score was 0.83.

Fatigue. The Multidimensional Fatigue Symptom Inventory–Short Form (MFSI) was used to assess total fatigue (Stein, Jacobsen, Blanchard, & Thors, 2004). The MFSI has strong psychometric properties and is useful in medically ill and nonmedically ill individuals (Donovan et al., 2014). Cronbach's alpha for the MFSI was 0.87.

Self-efficacy. The Cardiac Self-Efficacy Questionnaire (CSEQ) examines the role of patient self-efficacy for patients with coronary heart disease. The CSEQ has two factors (control symptoms and maintain function) and has high internal consistency and good convergent and discriminant validity (Sullivan, LaCroix, Russo, & Katon, 1998). We used the

CSEQ-Maintain Function subscale, and Cronbach's alpha was 0.85.

Inflammatory markers. Inflammation is implicated in the pathogenesis of HF and inflammatory biomarkers are used for risk stratification and prognosis (Bouras et al., 2014). We therefore assessed a relevant panel of inflammatory biomarkers known to be involved in adverse remodeling of the heart and the progression to heart failure, including CRP, TNF-α, IL-6, IFN-gamma & ST2 (Cosper, Harvey, & Leinwand, 2012; Huang, Yang, Xiang, & Wang, 2014; Seljeflot, Nilsson, Westheim, Bratseth, & Arnesen, 2011; Sun et al., 2014). Whole blood was preserved with EDTA, and following centrifugation, the plasma was stored at -80 °C until assay. Circulating levels of these biomarkers were determined by commercial ELISA (Meso Scale Discovery, Rockville, MD). Intra- and interassay coefficients were <5%.

Statistical Analyses

Prior to statistical analyses all data were tested for normality and homogeneity of variance using the Kolmogorov-Smirnov test; no transformations were conducted. Correlational and mediation analyses were run using SPSS software packages (Version 22.0; IBM, Armonk, NY). The SPSS Dimension Reduction factor analysis program was used to calculate a composite inflammatory index score comprised of circulating levels of CRP, TNF- α , IL-6, IFN-gamma & ST2. The resultant factor score Eigenvalue was 3.23, accounting for 53.8% of inflammatory variance. We examined mediation using the approach outlined by Baron and Kenny (1986). Using this mediation strategy, we ran a series of regression analyses were run: first regressing the dependent variable on the independent variable (Step 1/Path c), next regressing the mediating variable on the independent variable (Step 2/Path a), and last regressing the dependent variable on both the mediating variable (Step 3/Path b) and the independent variable (Step 4/Path c'). We further examined the significance of the product of the path coefficients $[(a^*b)$ an estimate of the indirect effect] using the Sobel test (Sobel, 1982).

Results

Table 1 presents biological, medical, psychosocial, and inflammatory biomarker characteristics of the patients.

Correlational Analyses

Gratitude was associated with better sleep (p < .01), less depressed mood (p < .01), less fatigue (p < .01), and better self-efficacy to maintain cardiac function (p < .01). Patients expressing more gratitude also had lower levels of the inflammatory biomarker index (p < .05).

Table 1 Sociodemographic, Medical, Psychosocial, and Inflammatory Biomarker Characteristics of Study Participants (N = 186)

| Body mass index (kg/m²) 30.2 (5.6) Gender (men) 95.3% Systolic blood pressure (mmHg) 134.2 (18.8) Diastolic blood pressure (mmHg) 77.1 (11.9) Left ventricular ejection fraction 64.8% (8.95) Concomitant disease 30.4% Diabetes mellitus 30.4% Myocardial infarction 17% Medications 39.1% ACE inhibitors 39.1% Beta blockers 44.2% Calcium channel blockers score 20.1% Statin 55.0% Aspirin 39.0% Diuretics 32.1% Anti-arrhythmic 3.9% Warfarin 10.6% Digoxin 2.0% | Characteristic | M/% (SD) |
|---|--|------------------|
| Gender (men)95.3%Systolic blood pressure (mmHg)134.2 (18.8)Diastolic blood pressure (mmHg)77.1 (11.9)Left ventricular ejection fraction64.8% (8.95)Concomitant disease30.4%Diabetes mellitus30.4%Myocardial infarction17%Medications39.1%ACE inhibitors39.1%Beta blockers44.2%Calcium channel blockers score20.1%Statin55.0%Aspirin39.0%Diuretics32.1%Anti-arrhythmic3.9%Warfarin10.6%Digoxin2.0%Psychosocial5.65 ± 1.09Gratitude Questionnaire (GQ-6)5.65 ± 1.09Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12)12.07 ± 5.71Beck Depression Inventory (BDI-IA) Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF)29.69 ± 21Cardiac Self-Efficacy Questionnaire— Maintain Function subscale16.08 ± 4.94Inflammatory biomarkers CRP (mg/dl)6.04 (9.2)IL-6 (pg/ml)2.21 (2.1)TNF-α (pg/ml)4.25 (3.0)IFN-gamma (ng/ml)2.39 (5.3) | Age (in years) | 66.4 (10.3) |
| Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg) Left ventricular ejection fraction Concomitant disease Diabetes mellitus Myocardial infarction Medications ACE inhibitors Beta blockers Calcium channel blockers score Statin Aspirin Diuretics Anti-arrhythmic Warfarin Digoxin Psychosocial Gratitude Questionnaire (GQ-6) Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) Beck Depression Inventory (BDI-IA) Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire Maintain Function subscale Inflammatory biomarkers CRP (mg/dl) IL-6 (pg/ml) TNF- α (pg/ml) IFN-gamma (ng/ml) 134.2 (18.8) 77.1 (11.9) 64.8% (8.95) 64.8% (9.9) 64.8% (9.9) 64.9% (94) 64.9% (94) 64.9% (94) 64.9% (94) 64.9% (94) 64.9% (94) 64. | Body mass index (kg/m ²) | 30.2 (5.6) |
| Diastolic blood pressure (mmHg) $77.1 (11.9)$ Left ventricular ejection fraction $64.8\% (8.95)$ Concomitant disease 30.4% Diabetes mellitus 30.4% Myocardial infarction 17% Medications 39.1% ACE inhibitors 39.1% Beta blockers 44.2% Calcium channel blockers score 20.1% Statin 55.0% Aspirin 39.0% Diuretics 32.1% Anti-arrhythmic 3.9% Warfarin 10.6% Digoxin 2.0% Psychosocial 3.9% Gratitude Questionnaire (GQ-6) 5.65 ± 1.09 Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) 12.07 ± 5.71 Beck Depression Inventory (BDI-IA) 8.84 ± 8.14 Pittsburgh Sleep Quality Index (PSQI) 8.92 ± 3.32 Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) 29.69 ± 21 Cardiac Self-Efficacy Questionnaire— Maintain Function subscale 16.08 ± 4.94 Inflammatory biomarkers $6.04 (9.2)$ CRP (mg/dl) $6.04 (9.2)$ IL-6 (pg/ml) $4.25 (3.0)$ IFN-gamma (ng/ml) $2.39 (5.3)$ | Gender (men) | 95.3% |
| Left ventricular ejection fraction 64.8% (8.95)Concomitant disease 30.4% Diabetes mellitus 30.4% Myocardial infarction 17% Medications 39.1% ACE inhibitors 39.1% Beta blockers 44.2% Calcium channel blockers score 20.1% Statin 55.0% Aspirin 39.0% Diuretics 32.1% Anti-arrhythmic 3.9% Warfarin 10.6% Digoxin 2.0% Psychosocial 30.2% Gratitude Questionnaire (GQ-6) 5.65 ± 1.09 Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) 12.07 ± 5.71 Beck Depression Inventory (BDI-IA) 8.84 ± 8.14 Pittsburgh Sleep Quality Index (PSQI) 8.92 ± 3.32 Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) 29.69 ± 21 Cardiac Self-Efficacy Questionnaire— Maintain Function subscale 16.08 ± 4.94 Inflammatory biomarkers 16.08 ± 4.94 CRP (mg/dl) 6.04 (9.2)IL-6 (pg/ml) 4.25 (3.0)IFN-gamma (ng/ml) 2.39 (5.3) | Systolic blood pressure (mmHg) | 134.2 (18.8) |
| Concomitant disease Diabetes mellitus Myocardial infarction Medications ACE inhibitors Beta blockers Calcium channel blockers score Statin Aspirin Diuretics Anti-arrhythmic Warfarin Digoxin Psychosocial Gratitude Questionnaire (GQ-6) Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) Beck Depression Inventory (BDI-IA) Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire— Maintain Function subscale Inflammatory biomarkers CRP (mg/dl) IL-6 (pg/ml) TNF-α (pg/ml) IFN-gamma (ng/ml) 39.1% 30.4% 30.4% 39.1% 39.0% | Diastolic blood pressure (mmHg) | 77.1 (11.9) |
| Diabetes mellitus 30.4% Myocardial infarction 17% Medications ACE inhibitors 39.1% Beta blockers 44.2% Calcium channel blockers score 20.1% Statin 55.0% Aspirin 39.0% Diuretics 32.1% Anti-arrhythmic 3.9% Warfarin 10.6% Digoxin 2.0% Psychosocial Gratitude Questionnaire (GQ-6) Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) 12.07 \pm 5.71 Beck Depression Inventory (BDI-IA) 8.84 \pm 8.14 Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire—Maintain Function subscale 16.08 \pm 4.94 Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | Left ventricular ejection fraction | 64.8% (8.95) |
| Myocardial infarction Medications ACE inhibitors Beta blockers Calcium channel blockers score Statin Aspirin Diuretics Anti-arrhythmic Warfarin Digoxin Psychosocial Gratitude Questionnaire (GQ-6) Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) Beck Depression Inventory (BDI-IA) Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire— Maintain Function subscale Inflammatory biomarkers CRP (mg/dl) IL-6 (pg/ml) TNF-α (pg/ml) IFN-gamma (ng/ml) A 4.25 (3.0) ITMS 39.1% 44.2% 20.1% 39.1% 44.2% 20.1% 55.0% Aspirin 39.0% 20.1% 55.0% Aspirin 39.0% 55.65 ± 1.09 6.04 (9.2) 4.21 (2.1) TNF-α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) | Concomitant disease | |
| MedicationsACE inhibitors39.1%Beta blockers44.2%Calcium channel blockers score20.1%Statin55.0%Aspirin39.0%Diuretics32.1%Anti-arrhythmic3.9%Warfarin10.6%Digoxin2.0%Psychosocial5.65 ± 1.09Gratitude Questionnaire (GQ-6)5.65 ± 1.09Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12)12.07 ± 5.71Beck Depression Inventory (BDI-IA)8.84 ± 8.14Pittsburgh Sleep Quality Index (PSQI)8.92 ± 3.32Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF)29.69 ± 21Cardiac Self-Efficacy Questionnaire— Maintain Function subscale29.69 ± 21Inflammatory biomarkers CRP (mg/dl)6.04 (9.2)IL-6 (pg/ml)6.04 (9.2)IL-6 (pg/ml)4.25 (3.0)IFN-gamma (ng/ml)2.39 (5.3) | Diabetes mellitus | 30.4% |
| ACE inhibitors Beta blockers Calcium channel blockers score Statin Aspirin Diuretics Anti-arrhythmic Warfarin Digoxin Psychosocial Gratitude Questionnaire (GQ-6) Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) Beck Depression Inventory (BDI-IA) Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire— Maintain Function subscale Inflammatory biomarkers CRP (mg/dl) IL-6 (pg/ml) TNF-α (pg/ml) IFN-gamma (ng/ml) 39.1% 44.2% 44.2% 44.2% 44.2% 44.2% 44.2% 44.2% 44.2% 44.2% 44.2% 44.2% 44.29 10.6% 5.65 ± 1.09 6.64 ± 8.14 6.08 ± 4.94 Inflammatory biomarkers CRP (mg/dl) 4.25 (3.0) IFN-gamma (ng/ml) 4.25 (3.0) | Myocardial infarction | 17% |
| Beta blockers 44.2% Calcium channel blockers score 20.1% Statin 55.0% Aspirin 39.0% Diuretics 32.1% Anti-arrhythmic 3.9% Warfarin 10.6% Digoxin 2.0% Psychosocial 3.9% Gratitude Questionnaire (GQ-6) 5.65 ± 1.09 Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) 12.07 ± 5.71 Beck Depression Inventory (BDI-IA) 8.84 ± 8.14 Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) 29.69 ± 21 Cardiac Self-Efficacy Questionnaire— Maintain Function subscale 16.08 ± 4.94 Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2)IL-6 (pg/ml) 2.21 (2.1)TNF-α (pg/ml) 4.25 (3.0)IFN-gamma (ng/ml) 2.39 (5.3) | Medications | |
| Calcium channel blockers score Statin 55.0% Aspirin 39.0% Diuretics 32.1% Anti-arrhythmic 3.9% Warfarin 10.6% Digoxin 2.0% Psychosocial Gratitude Questionnaire (GQ-6) 5.65 \pm 1.09 Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) 12.07 \pm 5.71 Beck Depression Inventory (BDI-IA) Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire— Maintain Function subscale Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 2.21 (2.1) TNF-α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | ACE inhibitors | 39.1% |
| Statin55.0%Aspirin39.0%Diuretics32.1%Anti-arrhythmic3.9%Warfarin10.6%Digoxin2.0%Psychosocial5.65 ± 1.09Gratitude Questionnaire (GQ-6)5.65 ± 1.09Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12)12.07 ± 5.71Beck Depression Inventory (BDI-IA)8.84 ± 8.14Pittsburgh Sleep Quality Index (PSQI)8.92 ± 3.32Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF)29.69 ± 21Cardiac Self-Efficacy Questionnaire— Maintain Function subscale16.08 ± 4.94Inflammatory biomarkers16.04 (9.2)CRP (mg/dl)6.04 (9.2)IL-6 (pg/ml)2.21 (2.1)TNF-α (pg/ml)4.25 (3.0)IFN-gamma (ng/ml)2.39 (5.3) | Beta blockers | 44.2% |
| Aspirin Diuretics Anti-arrhythmic Anti-arrhythmic Anti-arrhythmic Warfarin Digoxin Psychosocial Gratitude Questionnaire (GQ-6) Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) Beck Depression Inventory (BDI-IA) Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire— Maintain Function subscale Inflammatory biomarkers CRP (mg/dl) IL-6 (pg/ml) TNF-α (pg/ml) IFN-gamma (ng/ml) 39.0% 39.0% 39.0% 30.1% 30.20 5.65 ± 1.09 5.67 ± 5.71 5.71 5.71 5.72 ± 5.71 5.71 5.72 ± 5.71 5.73 ± 2.07 5.74 ± 2.07 5.74 ± 2.07 5.74 ± 2.07 5.75 ± 1.09 5.65 ± 1.09 | Calcium channel blockers score | 20.1% |
| Diuretics32.1%Anti-arrhythmic3.9%Warfarin10.6%Digoxin2.0%Psychosocial5.65 ± 1.09Gratitude Questionnaire (GQ-6)5.65 ± 1.09Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12)12.07 ± 5.71Beck Depression Inventory (BDI-IA)8.84 ± 8.14Pittsburgh Sleep Quality Index (PSQI)8.92 ± 3.32Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF)29.69 ± 21Cardiac Self-Efficacy Questionnaire— Maintain Function subscale16.08 ± 4.94Inflammatory biomarkersCRP (mg/dl)6.04 (9.2)IL-6 (pg/ml)2.21 (2.1)TNF-α (pg/ml)4.25 (3.0)IFN-gamma (ng/ml)2.39 (5.3) | Statin | 55.0% |
| Anti-arrhythmic 3.9% Warfarin 10.6% Digoxin 2.0% Psychosocial Gratitude Questionnaire (GQ-6) 5.65 \pm 1.09 Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) 12.07 \pm 5.71 Beck Depression Inventory (BDI-IA) 8.84 \pm 8.14 Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) 29.69 \pm 21 Cardiac Self-Efficacy Questionnaire—Maintain Function subscale 16.08 \pm 4.94 Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 2.21 (2.1) TNF- α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | Aspirin | 39.0% |
| Warfarin Digoxin 10.6% Digoxin 2.0% Psychosocial Gratitude Questionnaire (GQ-6) 5.65 \pm 1.09 Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT–SP12) 12.07 \pm 5.71 Beck Depression Inventory (BDI–IA) 8.84 \pm 8.14 Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire—Maintain Function subscale 16.08 \pm 4.94 Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 2.21 (2.1) TNF-α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | Diuretics | 32.1% |
| Digoxin 2.0% Psychosocial Gratitude Questionnaire (GQ-6) Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-SP12) Beck Depression Inventory (BDI-IA) Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire— Maintain Function subscale Inflammatory biomarkers CRP (mg/dl) IL-6 (pg/ml) TNF-α (pg/ml) IFN-gamma (ng/ml) 2.0% 12.07 ± 5.71 8.84 ± 8.14 8.92 ± 3.32 29.69 ± 21 29.69 ± 21 16.08 ± 4.94 Inflammatory biomarkers 16.08 ± 4.94 Inflammatory biomarkers $2.21 (2.1)$ TNF-α (pg/ml) IFN-gamma (ng/ml) $2.39 (5.3)$ | Anti-arrhythmic | 3.9% |
| Psychosocial Gratitude Questionnaire (GQ-6) 5.65 \pm 1.09 Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT–SP12) 12.07 \pm 5.71 Beck Depression Inventory (BDI–IA) 8.84 \pm 8.14 Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire—Maintain Function subscale 16.08 \pm 4.94 Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 2.21 (2.1) TNF-α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | Warfarin | 10.6% |
| Gratitude Questionnaire (GQ-6) | Digoxin | 2.0% |
| Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT–SP12) 12.07 \pm 5.71 Beck Depression Inventory (BDI–IA) 8.84 \pm 8.14 Pittsburgh Sleep Quality Index (PSQI) 8.92 \pm 3.32 Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire—Maintain Function subscale 16.08 \pm 4.94 Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 2.21 (2.1) TNF- α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | Psychosocial | |
| Therapy Spiritual Well-Being Scale (FACIT–SP12) 12.07 \pm 5.71 Beck Depression Inventory (BDI–IA) 8.84 \pm 8.14 Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire—Maintain Function subscale 16.08 \pm 4.94 Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 2.21 (2.1) TNF- α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | Gratitude Questionnaire (GQ-6) | 5.65 ± 1.09 |
| $\begin{array}{c} (FACIT-SP12) & 12.07 \pm 5.71 \\ Beck \ Depression \ Inventory \ (BDI-IA) & 8.84 \pm 8.14 \\ Pittsburgh \ Sleep \ Quality \ Index \ (PSQI) & 8.92 \pm 3.32 \\ Multidimensional \ Fatigue \ Symptom & 29.69 \pm 21 \\ Cardiac \ Self-Efficacy \ Questionnaire— & Maintain \ Function \ subscale & 16.08 \pm 4.94 \\ Inflammatory \ biomarkers & CRP \ (mg/dl) & 6.04 \ (9.2) \\ IL-6 \ (pg/ml) & 2.21 \ (2.1) \\ TNF-\alpha \ (pg/ml) & 4.25 \ (3.0) \\ IFN-gamma \ (ng/ml) & 2.39 \ (5.3) \\ \end{array}$ | Functional Assessment of Chronic Illness | |
| Beck Depression Inventory (BDI–IA) 8.84 ± 8.14 Pittsburgh Sleep Quality Index (PSQI) 8.92 ± 3.32 Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) 29.69 ± 21 Cardiac Self-Efficacy Questionnaire— Maintain Function subscale 16.08 ± 4.94 Inflammatory biomarkersCRP (mg/dl) 6.04 (9.2)IL-6 (pg/ml) 2.21 (2.1)TNF-α (pg/ml) 4.25 (3.0)IFN-gamma (ng/ml) 2.39 (5.3) | Therapy Spiritual Well-Being Scale | |
| Pittsburgh Sleep Quality Index (PSQI) Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) Cardiac Self-Efficacy Questionnaire— Maintain Function subscale Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 2.21 (2.1) TNF- α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | (FACIT–SP12) | |
| $\begin{tabular}{lllllllllllllllllllllllllllllllllll$ | Beck Depression Inventory (BDI-IA) | |
| $ \begin{array}{llllllllllllllllllllllllllllllllllll$ | | 8.92 ± 3.32 |
| Cardiac Self-Efficacy Questionnaire— Maintain Function subscale 16.08 \pm 4.94 Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 2.21 (2.1) TNF- α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | | |
| | • | 29.69 ± 21 |
| Inflammatory biomarkers CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 2.21 (2.1) TNF-α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | | |
| CRP (mg/dl) 6.04 (9.2) IL-6 (pg/ml) 2.21 (2.1) TNF-α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | | 16.08 ± 4.94 |
| IL-6 (pg/ml) 2.21 (2.1) TNF-α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | , | |
| TNF-α (pg/ml) 4.25 (3.0) IFN-gamma (ng/ml) 2.39 (5.3) | . 6 | |
| IFN-gamma (ng/ml) 2.39 (5.3) | | |
| | | |
| ST-2 (pg/ml) 17.9 (8.2) | | , , |
| | ST-2 (pg/ml) | 17.9 (8.2) |

Spiritual well-being was associated with better sleep p < .01), less depressed mood (p < .01), less fatigue (p < .01), and better self-efficacy to maintain cardiac function (p < .01; see Table 2).

Gratitude as a Mediator of the Relationship Between Spirituality and Physical and Mental Health

Mediation analyses were conducted to examine whether gratitude mediates the relationship between spiritual well-being and aspects of physical and mental health. These effects were as follows (Figures 1 and 2):

Sleep. In Step 1 of the mediation model, the regression of subjective sleep quality (PSQI) on spiritual well-being (FACIT-SP12) was significant $(R^2 = .08, \beta = -.284), t(166) =$ -3.82, p < .001. Step 2 showed that the regression of spiritual well-being (FACIT-SP12) on the mediator, trait gratitude (GQ-6), was also significant ($R^2 = .31$, $\beta = .552$), t(169) = 8.58, p < .001. Step 3 of the mediation process showed that the mediator, trait gratitude (GQ-6), controlling spiritual well-being (FACIT-SP12), was significantly related to sleep quality (PSQI; $R^2 = .11$, $\beta = -.213$), t(167) = -2.42, p = .02. Step 4 of the analyses revealed that, when controlling for trait gratitude (GQ-6), spiritual well-being (FACIT-SP12) no longer remained a significant predictor of subjective sleep quality (PSQI; $R^2 = .11$, $\beta = -.167$), t(167) = 1.89, p = .06, indicating that the beneficial effect of spirituality on sleep exerts its effect through gratitude. We further examined the strength of the indirect or mediated effect using the Sobel test and confirmed its significance (z = -2.35, SE = .03, p = .02).

Depressed mood. In Step 1, we regressed depressed mood (BDI–IA) on spiritual wellbeing (FACIT–SP12) and this relationship was significant ($R^2 = .13$, $\beta = -.355$), t(157) = -4.765, p < .001. Step 2 outputs are the same in all four mediation models. Step 3 demonstrated that the mediator, trait gratitude (GQ–6) was related to depressed mood (BDI–IA) when controlling for spiritual well-being (FACIT–SP12; $R^2 = .23$, $\beta = -3.84$), t(158) = -4.536, p < .001. Step 4 indicated that when controlling for trait gratitude (GQ–6), the relationship between spiritual well-being (FACIT–SP12) and depressed mood (BDI–IA) is no longer signifi-

Table 2
Correlations Among Administered Questionnaires

| Instrument | Gratitude Questionnaire (GQ-6) | Spiritual Well- Being Scale (FACIT-SP12) |
|--|--------------------------------------|--|
| Gratitude Questionnaire (GQ-6) | | _ |
| Spiritual Well-Being Scale (FACIT–SP12) | .55** | |
| Beck Depression Inventory (BDI–IA) | 46** | 35** |
| Pittsburgh Sleep Quality Index (PSQI) | 32** | 28** |
| Multidimensional Fatigue Symptom Inventory—Short Form (MFSI-SF) | 50** | 50** |
| Cardiac Self-Efficacy Questionnaire–Maintain Function subscale (CSEQ-MF) | .43** | .46*** |
| Inflammatory Index (CRP, TNF-α, IL-6, IFN-gamma & ST2) | 17* | 10 |

^{*} p < .05. ** p < .01. *** p < .001.

cant ($R^2 = .23$, $\beta = -.384$), t(156) = -1.663, p = .10, indicating that gratitude fully mediates the relationship between spiritual well-being and depressed mood. We again confirmed the significance of the mediation using the Sobel test (z = -4.00, SE = .075, p < .001).

Fatigue. When examining fatigue (MFSI), there was again evidence of relationship with

spiritual well-being (FACIT–SP12; $R^2 = .25$, $\beta = -.499$), t(163) = -7.342, p < .001, in Step 1, and Step 3 again demonstrated a relationship between trait gratitude (GQ–6) and fatigue (MFSI) when controlling for spiritual well-being (FACIT–SP12; $R^2 = .33$, $\beta = -.335$), t(162) = -4.318, p < .001. However, Step 4 revealed that the relationship between




Figure 1. Trait gratitude significantly mediated the relationships between spiritual wellbeing and sleep quality and spiritual wellbeing and depressed mood. Path values are unstandardized regression coefficients with standard errors in parentheses. Mediated (indirect) effects were derived from the product of paths a and b and examined using the Sobel test (1982). Panel A: Trait gratitude fully mediated the relationship between spiritual well-being and sleep quality (z=-2.45, SE=.03, p=.02). Panel B: Trait gratitude fully mediated the relationship between spiritual well-being and depressed mood (z=-4.00, SE=.08, p<.001). * p<.05. ** p<.01.




Figure 2. Trait gratitude significantly mediated the relationships between spiritual wellbeing and fatigue and spiritual well-being and self-efficacy to maintain cardiac function. Path values are unstandardized regression coefficients with standard errors in parentheses. Mediated (indirect) effects were derived from the product of paths a and b and examined using the Sobel test (1982). Panel A: Trait gratitude partially mediated the relationship between spiritual well-being and fatigue (z=-3.849, SE=.18, p<.001). Panel B: Trait gratitude partially mediated the relationship between spiritual well-being and cardiac-specific self-efficacy (z=2.91, SE=.04, p<.01). ** p<.05. *** p<.01.

spiritual well-being (FACIT–SP12) and fatigue (MFSI) remains significant controlling for the putative mediator, gratitude (GQ–6; $R^2=.33$, $\beta=-.312$), t(162)=-4.020, p<.001. Although the c^1 path remains significant, the Sobel test of the indirect or mediated pathway was also significant (z=-3.85, SE=.18, p<.001), providing evidence to suggest that gratitude partially mediates the relationship between spiritual well-being and fatigue.

Self-efficacy to maintain cardiac function. In our analyses examining self-efficacy to maintain cardiac function (CSEQ), in Step 1 there was a significant relationship with spiritual well-being (FACIT–SP12; $R^2 = .21$, $\beta = .456$), t(159) = 6.453, p < .001. In Step 3, there was evidence of a relationship between trait grati-

tude (GQ-6) and self-efficacy to maintain cardiac function (CSEQ) when controlling for spiritual well-being (FACIT-SP12; $R^2=.25$, $\beta=.256$), t(158)=3.10, p=.002. In Step 4, the relationship between spiritual well-being (FACIT-SP12) and self-efficacy to maintain cardiac function (CSEQ) remains significant when controlling for our hypothesized mediator, gratitude (GQ-6; $R^2=.25$, $\beta=.314$), t(158)=3.087, p<.001. Again though, the Sobel test of the indirect or mediated pathway was also significant (z=2.91, SE=.04, p=.003), suggesting that gratitude partially mediates the relationship between spirituality and cardiac-specific self-efficacy.

Inflammatory index. In our mediation analyses examining inflammation, there was no

relationship between spiritual well-being and the inflammatory index ($R^2 = .01$, $\beta = -1.02$), t(140) = -1.21, p = 23. Similarly, Steps 3 and 4 of the mediation analyses were not significant and consequently no relationship between spirituality and inflammation for gratitude to potentially mediate.

Discussion

In Stage B asymptomatic HF patients, we found that gratitude was related to better mood and sleep, more self-efficacy, and lower fatigue and inflammation. Spiritual wellbeing was related to each of these as well, with the exception of the inflammatory index. When examining these relationships in more depth, we found that gratitude fully mediated the beneficial effects of spiritual well-being on sleep and depressed mood and partially mediated the relationships between spiritual well-being and fatigue and spiritual wellbeing and cardiac-specific self-efficacy. Stage B patients are asymptomatic but at high risk for developing symptomatic (Stage C) HF, and thus present an opportunity to implement early therapeutic interventions to ultimately reduce morbidity and mortality (Hunt et al., 2005b). Interventions designed to increase gratitude do improve psychological wellbeing (Wood et al., 2010).

Research findings from gratitude studies suggest that gratitude, because of its orientation toward positive appraisal, is likely incompatible with the "negative triad" of beliefs associated with depression (Evans et al., 2005). Indeed, gratitude is related to both hedonic well-being (i.e., subjective wellbeing, which is characterized by higher positive affect, lower negative affect, and life satisfaction) and eudaimonic well-being (i.e., psychological well-being, which is characterized by aspects such as environmental mastery, personal autonomy, purpose in life, positive relations with others, and personal growth (Evans et al., 2005; Ryff & Keyes, 1995). In turn, both hedonic and eudaimonic well-being have been linked to reduced likelihood of depression (e.g., Pressman & Cohen, 2005; Wood et al., 2008), as well as alterations in immune function associated with improved health (Ryff, Singer, & Dienberg Love, 2004). Thus one potential pathway by which gratitude may promote well-being, as well as better cardiovascular health in HF, is through the enhancement of both subjective (hedonic) and psychological (eudaimonic) well-being (Wood et al., 2010). It is important to note that a recent review reports that well-being is associated with improved cardiovascular health, with hedonic well-being noted to be associated with improved biological function and restorative health behaviors; the authors noted a need for more data on the potential impact of eudaimonic well-being on cardiovascular outcomes (Boehm & Kubzansky, 2012).

Another potential pathway by which gratitude may enhance health is via shifts in affective perceptions of daily life events from negative to positive. The chronic hassles and uplifts scale is an index of daily perceptions of events as either hassles (negative) or uplifts (positive), and has been found to correlate with mood, health, and positive affect (Folkman & Lazarus, 1988). In a study by our group, we reported independent relationships of uplifts (frequency and intensity) and inflammatory markers that were independent of sociodemographic, behavioral, medical and psychological variables such as hassles, depression, and perceived stress. (Jain, Mills, von Kanel, Hong, & Dimsdale, 2007), suggesting that positive perceptions of daily life events is uniquely associated with inflammation. Gratitude may reduce inflammatory markers in Stage B HF patients through changes in affective perceptions of daily life.

Gratitude was associated with lower depressed mood scores in these patients, and mediated the relationship between spiritual well-being and mood. Prior studies report that self-rated spiritual well-being is strongly and independently associated with fewer depressive symptoms in stage B HF patients (Peterman et al., 2002). This is clinically significant since the presence of depressive symptoms in cardiovascular diseases such as HF is associated with increased risk of cardiovascular hospitalization and mortality (Johnson et al., 2012; Kato et al., 2012; Rutledge, Reis, Linke, Greenberg, & Mills, 2006). Typical risk factors associated with depression in HF include increasing age, poor physical fitness, poor sleep, fatigue, and inflammation (Alosco et al., 2013; Jimenez & Mills, 2012; Kupper, Widdershoven, & Pedersen, 2012; Mills et al., 2009; Shimizu, Suzuki, Okumura, & Yamada, 2013; Sin, 2012; Tang, Yu, & Yeh, 2010). For Stage B HF patients, finding correlates of depressive symptoms is particularly important as an avenue for potentially forestalling development of symptomatic Stage C disease, which is significantly associated with poorer quality of life and increased morbidity and mortality (Ammar et al., 2007).

In terms of gratitude interventions, in a recent double-blind randomized controlled trial in health care practitioners, Cheng, Tsui, and Lam (2014) showed that a 4-week gratitude journaling intervention, as compared with journaling about hassles, led to a significant reduction in stress and improved mood. Other interventions focusing on "thoughts of gratitude" reveal that gratitude interventions have a significant effect on improving daily positive emotions (Ouweneel, Le Blanc, & Schaufeli, 2014). Few studies, however, have examined the potential benefits of gratitude interventions for HF despite studies describing the importance of gratitude in alleviating the struggles associated with living with HF (Sacco et al., 2014). Sacco et al. developed an 8-week phone-based positive psychology intervention for patients hospitalized with acute cardiac disease (acute coronary syndrome or decompensated heart failure), which comprised positive psychology exercises adapted for this population with a focus on gratitude, optimism, and kindness. Their initial findings include that the intervention is well accepted in cardiac patients; further outcome data are pending (Sacco et al., 2014).

It is worth noting that though gratitude is considered a positive psychological factor, it is not necessarily good for all people under all circumstances, for example, displaced gratitude under conditions of exploitation; gratitude with discernment is worth cultivating. As far as the scientific literature, the vast majority of research demonstrates positive, not negative, consequences of gratitude and that cultivating gratitude doesn't necessarily reduce seeing the negative features of life but rather offers or encourages seeing the positive in life (Eaton, Bradley, & Morrissey, 2014; Wood et al., 2008).

Summary

Gratitude and spiritual well-being are key positive factors to consider in this population. We documented that an attitude of gratitude is related to better mood and sleep, less fatigue, more self-efficacy, and a lower cellular inflammatory index. Untangling these relationships further, we found that higher trait gratitude mediates spiritual well-being's positive effects on better sleep and less depressed mood (and to a lesser degree fatigue and cardiac-specific selfefficacy). These are potentially important observations because depressed mood and poor sleep are associated with worse prognosis in HF as well as other cardiac populations, and therefore interventions that increase levels of gratitude may have clinical implications for improving health outcomes (Canivet, Nilsson, Lindeberg, Karasek, & Ostergren, 2014; Huffman, Celano, Beach, Motiwala, & Januzzi, 2013; Rutledge et al., 2006). Given that interventions to increase gratitude are relatively simple and of low cost, efforts to increase gratitude in HF patients' lives may be of potential clinical value and represent a treatment target for improving well-being.

References

Alosco, M. L., Spitznagel, M. B., van Dulmen, M., Raz, N., Cohen, R., Sweet, L. H., . . . Gunstad, J. (2013). Depressive symptomatology, exercise adherence, and fitness are associated with reduced cognitive performance in heart failure. *Journal of Aging and Health*, 25, 459–477. http://dx.doi.org/ 10.1177/0898264312474039

Ammar, K. A., Jacobsen, S. J., Mahoney, D. W., Kors, J. A., Redfield, M. M., Burnett, J. C., Jr., & Rodeheffer, R. J. (2007). Prevalence and prognostic significance of heart failure stages: Application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. *Circulation*, 115, 1563–1570. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.666818

Baron, R. M., & Kenny, D. A. (1986). The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. *Journal of Personality and Social Psychology*, 51, 1173–1182. http://dx.doi.org/10.1037/0022-3514.51.6.1173

Beck, A. T. (1978). Depression inventory. Philadelphia, PA: Center for Cognitive Therapy.

Bekelman, D. B., Rumsfeld, J. S., Havranek, E. P., Yamashita, T. E., Hutt, E., Gottlieb, S. H., . . .

- Kutner, J. S. (2009). Symptom burden, depression, and spiritual well-being: A comparison of heart failure and advanced cancer patients. *Journal of General Internal Medicine*, *24*, 592–598. http://dx.doi.org/10.1007/s11606-009-0931-y
- Boehm, J. K., & Kubzansky, L. D. (2012). The heart's content: The association between positive psychological well-being and cardiovascular health. *Psychological Bulletin*, *138*, 655–691. http://dx.doi.org/10.1037/a0027448
- Bonelli, R. M., & Koenig, H. G. (2013). Mental disorders, religion and spirituality 1990 to 2010: A systematic evidence-based review. *Journal of Religion and Health*, 52, 657–673. http://dx.doi.org/ 10.1007/s10943-013-9691-4
- Bouras, G., Giannopoulos, G., Hatzis, G., Alexopoulos, D., Leventopoulos, G., & Deftereos, S. (2014). Inflammation and chronic heart failure: From biomarkers to novel anti-inflammatory therapeutic strategies. *Medicinal Chemistry*, 10, 682–699. http://dx.doi.org/ 10.2174/1573406410666140318113325
- Büssing, A., Wirth, A. G., Reiser, F., Zahn, A., Humbroich, K., Gerbershagen, K., . . . Baumann, K. (2014). Experience of gratitude, awe and beauty in life among patients with multiple sclerosis and psychiatric disorders. *Health and Quality of Life Outcomes*, 12, 63. http://dx.doi.org/10.1186/1477-7525-12-63
- Buysse, D. J., Reynolds, C. F., III, Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. *Psychiatry Research*, 28, 193–213. http://dx.doi.org/10.1016/ 0165-1781(89)90047-4
- Canivet, C., Nilsson, P. M., Lindeberg, S. I., Karasek, R., & Östergren, P. O. (2014). Insomnia increases risk for cardiovascular events in women and in men with low socioeconomic status: A longitudinal, register-based study. *Journal of Psychosomatic Research*, 76, 292–299. http://dx.doi.org/ 10.1016/j.jpsychores.2014.02.001
- Carpenter, J. S., & Andrykowski, M. A. (1998). Psychometric evaluation of the Pittsburgh Sleep Quality Index. *Journal of Psychosomatic Re*search, 45, 5–13. http://dx.doi.org/10.1016/S0022-3999(97)00298-5
- Cheng, S. T., Tsui, P. K., & Lam, J. H. (2014). Improving mental health in health care practitioners: Randomized controlled trial of a gratitude intervention. *Journal of Consulting and Clinical Psychology*, 83, 177–186.
- Cosper, P. F., Harvey, P. A., & Leinwand, L. A. (2012). Interferon-γ causes cardiac myocyte atrophy via selective degradation of myosin heavy chain in a model of chronic myocarditis. *American Journal of Pathology*, 181, 2038–2046. http://dx.doi.org/10.1016/j.ajpath.2012.08.040

- Delaney, C., Barrere, C., & Helming, M. (2011). The influence of a spirituality-based intervention on quality of life, depression, and anxiety in community-dwelling adults with cardiovascular disease: A pilot study. *Journal of Holistic Nursing*, 29, 21–32. http://dx.doi.org/10.1177/089801011 0378356
- Desai, A. S., & Stevenson, L. W. (2012). Rehospitalization for heart failure: Predict or prevent? Circulation, 126, 501–506. http://dx.doi.org/10.1161/CIRCULATIONAHA.112.125435
- Donovan, K. A., Stein, K. D., Lee, M., Leach, C. R., Ilozumba, O., & Jacobsen, P. B. (2014). Systematic review of the Multidimensional Fatigue Symptom Inventory–Short Form. Supportive Care in Cancer, 23, 191–212.
- Dubois, C. M., Beach, S. R., Kashdan, T. B., Nyer, M. B., Park, E. R., Celano, C. M., & Huffman, J. C. (2012). Positive psychological attributes and cardiac outcomes: Associations, mechanisms, and interventions. *Psychosomatics*, 53, 303–318. http://dx.doi.org/10.1016/j.psym.2012.04.004
- Eaton, R. J., Bradley, G., & Morrissey, S. (2014).
 Positive predispositions, quality of life and chronic illness. *Psychology, Health and Medicine*, 19, 473–489. http://dx.doi.org/10.1080/13548506.2013.824593
- Eisen, A., Benderly, M., Behar, S., Goldbourt, U., & Haim, M. (2014). Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease. *American Heart Journal*, 167, 707–714. http://dx.doi.org/10.1016/j.ahj.2014 .01.008
- Evans, J., Heron, J., Lewis, G., Araya, R., Wolke, D., & the ALSPAC study team. (2005). Negative selfschemas and the onset of depression in women: Longitudinal study. *The British Journal of Psychi*atry, 186, 302–307. http://dx.doi.org/10.1192/bjp .186.4.302
- Folkman, S., & Lazarus, R. S. (1988). The relationship between coping and emotion: Implications for theory and research. *Social Science & Medicine*, 26, 309–317. http://dx.doi.org/10.1016/0277-9536(88)90395-4
- Froh, J. J., Fan, J., Emmons, R. A., Bono, G., Huebner, E. S., & Watkins, P. (2011). Measuring gratitude in youth: Assessing the psychometric properties of adult gratitude scales in children and adolescents. *Psychological Assessment*, 23, 311–324. http://dx.doi.org/10.1037/a0021590
- Huang, M., Yang, D., Xiang, M., & Wang, J. (2014).
 Role of interleukin-6 in regulation of immune responses to remodeling after myocardial infarction.
 Heart Failure Reviews, 20, 25–38.
- Huffman, J. C., Celano, C. M., Beach, S. R., Motiwala, S. R., & Januzzi, J. L. (2013). Depression and cardiac disease: Epidemiology, mechanisms, and diagnosis. *Cardiovascular Psychiatry and*

- *Neurology*, 2013, 695925. http://dx.doi.org/ 10.1155/2013/695925
- Huffman, J. C., Mastromauro, C. A., Boehm, J. K., Seabrook, R., Fricchione, G. L., Denninger, J. W., & Lyubomirsky, S. (2011). Development of a positive psychology intervention for patients with acute cardiovascular disease. *Heart International*, 6, e14. http://dx.doi.org/10.4081/hi.2011.e14
- Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., . . . the American College of Cardiology, & the American Heart Association Task Force on Practice Guidelines, the American College of Chest Physicians, the International Society for Heart and Lung Transplantation, & the Heart Rhythm Society. (2005a). ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation, 112, e154-e235. http://dx.doi.org/10.1161/ CIRCULATIONAHA.105.167586
- Hunt, S. A., the American College of Cardiology, & the American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). (2005b). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *Journal of the American College of Cardiology*, 46, e1–e82. http://dx.doi.org/10.1016/j.jacc.2005.08.022
- Jain, S., Mills, P. J., von Känel, R., Hong, S., & Dimsdale, J. E. (2007). Effects of perceived stress and uplifts on inflammation and coagulability. *Psychophysiology*, 44, 154–160. http://dx.doi.org/10.1111/j.1469-8986.2006.00480.x
- Jiménez, J. A., & Mills, P. J. (2012). Neuroimmune mechanisms of depression in heart failure. *Meth-ods in Molecular Biology*, 934, 165–182. http://dx.doi.org/10.1007/978-1-62703-071-7_9
- Johnson, T. J., Basu, S., Pisani, B. A., Avery, E. F., Mendez, J. C., Calvin, J. E., Jr., & Powell, L. H. (2012). Depression predicts repeated heart failure hospitalizations. *Journal of Cardiac Failure*, 18, 246–252. http://dx.doi.org/10.1016/j.cardfail.2011 .12.005

- Kato, N., Kinugawa, K., Shiga, T., Hatano, M., Takeda, N., Imai, Y., . . . Nagai, R. (2012). Depressive symptoms are common and associated with adverse clinical outcomes in heart failure with reduced and preserved ejection fraction. *Journal of Cardiology*, 60, 23–30. http://dx.doi.org/10.1016/j .jjcc.2012.01.010
- Krum, H., & Stewart, S. (2006). Chronic heart failure: Time to recognize this major public health problem. *The Medical Journal of Australia*, 184, 147–148.
- Kupper, N., Widdershoven, J. W., & Pedersen, S. S. (2012). Cognitive/affective and somatic/affective symptom dimensions of depression are associated with current and future inflammation in heart failure patients. *Journal of Affective Disorders*, 136, 567–576. http://dx.doi.org/10.1016/j.jad.2011.10 .029
- Lambert, N. M., Graham, S. M., & Fincham, F. D. (2009). A prototype analysis of gratitude: Varieties of gratitude experiences. *Personality and Social Psychology Bulletin*, 35, 1193–1207. http://dx.doi.org/10.1177/0146167209338071
- Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., . . . the Chamber Quantification Writing Group, & the American Society of Echocardiography's Guidelines and Standards Committee, & the European Association of Echocardiography. (2005). Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *Journal of the American Society of Echocardiography*, 18, 1440–1463. http://dx.doi.org/10.1016/j.echo.2005.10.005
- Mccullough, M. E., Emmons, R. A., & Tsang, J. A. (2002). The grateful disposition: A conceptual and empirical topography. *Journal of Personality and Social Psychology*, 82, 112–127. http://dx.doi.org/10.1037/0022-3514.82.1.112
- Mills, P. J., Dimsdale, J. E., Natarajan, L., Ziegler, M. G., Maisel, A., & Greenberg, B. H. (2009). Sleep and health-related quality of life in heart failure. *Congestive Heart Failure*, *15*, 228–233. http://dx.doi.org/10.1111/j.1751-7133.2009.00106.x
- Morgenstern, L. B., Sánchez, B. N., Skolarus, L. E., Garcia, N., Risser, J. M., Wing, J. J., . . . Lisabeth, L. D. (2011). Fatalism, optimism, spirituality, depressive symptoms, and stroke outcome: A population-based analysis. *Stroke*, 42, 3518–3523. http://dx.doi.org/10.1161/STROKEAHA.111 .625491
- Naghi, J. J., Philip, K. J., Phan, A., Cleenewerck, L., & Schwarz, E. R. (2012). The effects of spirituality and religion on outcomes in patients with chronic

- heart failure. *Journal of Religion and Health, 51,* 1124–1136. http://dx.doi.org/10.1007/s10943-010-9419-7
- Ouweneel, E., Le Blanc, P. M., & Schaufeli, W. B. (2014). On being grateful and kind: Results of two randomized controlled trials on study-related emotions and academic engagement. *The Journal of Psychology: Interdisciplinary and Applied, 148,* 37–60. http://dx.doi.org/10.1080/00223980.2012 .742854
- Peterman, A. H., Fitchett, G., Brady, M. J., Hernandez, L., & Cella, D. (2002). Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy—Spiritual Well-Being Scale (FACIT–Sp). *Annals of Behavioral Medicine*, 24, 49–58. http://dx.doi.org/10.1207/S15324796ABM2401_06
- Pressman, S. D., & Cohen, S. (2005). Does positive affect influence health? *Psychological Bulletin*, 131, 925–971.
- Rozanski, A. (2014). Behavioral cardiology: Current advances and future directions. *Journal of the American College of Cardiology*, 64, 100–110. http://dx.doi.org/10.1016/j.jacc.2014.03.047
- Rutledge, T., Reis, V. A., Linke, S. E., Greenberg, B. H., & Mills, P. J. (2006). Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. *Journal of the American College of Cardiology*, 48, 1527–1537. http://dx.doi.org/10.1016/j .jacc.2006.06.055
- Ryff, C. D., & Keyes, C. L. (1995). The structure of psychological well-being revisited. *Journal of Personality and Social Psychology*, 69, 719–727. http://dx.doi.org/10.1037/0022-3514.69.4.719
- Ryff, C. D., Singer, B. H., & Dienberg Love, G. (2004). Positive health: Connecting well-being with biology. *Philosophical Transactions of the Royal Society of London Series B, Biological Sciences*, 359, 1383–1394. http://dx.doi.org/10.1098/rstb.2004.1521
- Sacco, S. J., Park, C. L., Suresh, D. P., & Bliss, D. (2014). Living with heart failure: Psychosocial resources, meaning, gratitude and well-being. *Heart* & *Lung*, 43, 213–218. http://dx.doi.org/10.1016/j .hrtlng.2014.01.012
- Seljeflot, I., Nilsson, B. B., Westheim, A. S., Bratseth, V., & Arnesen, H. (2011). The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training. *Journal of Cardiac Failure*, 17, 135–142. http://dx.doi.org/10.1016/j.cardfail.2010.09.003
- Shimizu, Y., Suzuki, M., Okumura, H., & Yamada, S. (2013). Risk factors for onset of depression after heart failure hospitalization. *Journal of Cardiol*ogy, 64, 37–42.

- Sin, M. K. (2012). Personal characteristics predictive of depressive symptoms in Hispanics with heart failure. *Issues in Mental Health Nursing*, *33*, 522–527. http://dx.doi.org/10.3109/01612840.2012 .687438
- Smyth, C. (2000). The Pittsburgh Sleep Quality Index (PSQI). *Insight (American Society of Ophthalmic Registered Nurses)*, 25, 97–98. http://dx.doi.org/10.1067/min.2000.107649
- Sobel, M. E. (1982). Asymptotic confidence intervals for indirect effects in structural equation models. In S. Leinhardt (Ed.), *Sociological methodology*, 1985 (pp. 290–312). Washington, DC: American Sociological Association.
- Stein, K. D., Jacobsen, P. B., Blanchard, C. M., & Thors, C. (2004). Further validation of the multidimensional fatigue symptom inventory-short form. *Journal of Pain and Symptom Management*, 27, 14–23. http://dx.doi.org/10.1016/j.jpainsymman.2003.06.003
- Sullivan, M. D., LaCroix, A. Z., Russo, J., & Katon, W. J. (1998). Self-efficacy and self-reported functional status in coronary heart disease: A sixmonth prospective study. *Psychosomatic Medicine*, 60, 473–478. http://dx.doi.org/10.1097/ 00006842-199807000-00014
- Sun, R. R., Lu, L., Liu, M., Cao, Y., Li, X. C., Liu, H., . . . Zhang, P. Y. (2014). Biomarkers and heart disease. European Review for Medical and Pharmacological Sciences, 18, 2927–2935.
- Tang, W. R., Yu, C. Y., & Yeh, S. J. (2010). Fatigue and its related factors in patients with chronic heart failure. *Journal of Clinical Nursing*, 19, 69–78. http://dx.doi.org/10.1111/j.1365-2702.2009 .02959.x
- Viganego, F., & Le Jemtel, T. H. (2007). Progression and management of chronic heart failure. *Panmin-erva Medica*, 49, 109–118.
- Wang, G., Zhang, Z., Ayala, C., Wall, H. K., & Fang, J. (2010). Costs of heart failure-related hospitalizations in patients aged 18 to 64 years. *The Amer*ican Journal of Managed Care, 16, 769–776.
- Wang, Y. P., & Gorenstein, C. (2013). Psychometric properties of the Beck Depression Inventory–II: A comprehensive review. Revista Brasileira de Psiquiatria, 35, 416–431. http://dx.doi.org/ 10.1590/1516-4446-2012-1048
- Warber, S. L., Ingerman, S., Moura, V. L., Wunder, J., Northrop, A., Gillespie, B. W., . . . Rubenfire, M. (2011). Healing the heart: A randomized pilot study of a spiritual retreat for depression in acute coronary syndrome patients. EXPLORE: The Journal of Science and Healing, 7, 222–233. http://dx .doi.org/10.1016/j.explore.2011.04.002
- Whelan-Gales, M. A., Quinn Griffin, M. T., Maloni, J., & Fitzpatrick, J. J. (2009). Spiritual well-being, spiritual practices, and depressive symptoms among elderly patients hospitalized with acute

heart failure. *Geriatric Nursing*, 30, 312–317. http://dx.doi.org/10.1016/j.gerinurse.2009.04.001 Wood, A. M., Froh, J. J., & Geraghty, A. W. (2010). Gratitude and well-being: A review and theoretical integration. *Clinical Psychology Review*, 30, 890–905. http://dx.doi.org/10.1016/j.cpr.2010.03.005 Wood, A. M., Maltby, J., Stewart, N., Linley, P. A., & Joseph, S. (2008). A social-cognitive model of

trait and state levels of gratitude. *Emotion*, *8*, 281–290. http://dx.doi.org/10.1037/1528-3542.8.2.281

Received November 2, 2014
Revision received December 29, 2014
Accepted January 19, 2015

Members of Underrepresented Groups: Reviewers for Journal Manuscripts Wanted

If you are interested in reviewing manuscripts for APA journals, the APA Publications and Communications Board would like to invite your participation. Manuscript reviewers are vital to the publications process. As a reviewer, you would gain valuable experience in publishing. The P&C Board is particularly interested in encouraging members of underrepresented groups to participate more in this process.

If you are interested in reviewing manuscripts, please write APA Journals at Reviewers@apa.org. Please note the following important points:

- To be selected as a reviewer, you must have published articles in peer-reviewed journals. The experience of publishing provides a reviewer with the basis for preparing a thorough, objective review.
- To be selected, it is critical to be a regular reader of the five to six empirical journals
 that are most central to the area or journal for which you would like to review. Current
 knowledge of recently published research provides a reviewer with the knowledge base
 to evaluate a new submission within the context of existing research.
- To select the appropriate reviewers for each manuscript, the editor needs detailed information. Please include with your letter your vita. In the letter, please identify which APA journal(s) you are interested in, and describe your area of expertise. Be as specific as possible. For example, "social psychology" is not sufficient—you would need to specify "social cognition" or "attitude change" as well.
- Reviewing a manuscript takes time (1–4 hours per manuscript reviewed). If you are selected to review a manuscript, be prepared to invest the necessary time to evaluate the manuscript thoroughly.

APA now has an online video course that provides guidance in reviewing manuscripts. To learn more about the course and to access the video, visit http://www.apa.org/pubs/authors/review-manuscript-ce-video.aspx.